Todos os estudos
RecrutamentoFASE3INTERVENCIONISTA

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Researchers are exploring new treatments for advanced ovarian cancer. After initial surgery and chemotherapy, many women receive maintenance treatment to prevent the cancer from returning or growing. This study is testing if a new targeted therapy, called sacituzumab tirumotecan (sac-TMT), either alone or with another standard drug called bevacizumab, can extend the time before the cancer worsens. This is compared to current standard care options, which include bevacizumab maintenance or close observation. The aim is to find out if sac-TMT can help women live longer without their cancer progressing, for those whose cancer has responded well to their first round of treatment.

Em resumo

Status
Recrutamento
Fase
FASE3
Patrocinador
Merck Sharp & Dohme LLC
Meta de inscrição
900
Iniciar
16 de fev de 2026
Conclusão estimada
25 Feb 2033

Sobre o que é este estudo?

When someone is diagnosed with ovarian cancer, doctors often try to remove as much of the cancer as possible with surgery. After surgery, chemotherapy is typically given to kill any remaining cancer cells. The next step is often to keep the cancer from coming back or growing, and this is where this study comes in.

Currently, after chemotherapy, some people receive maintenance treatment, which is like a protective shield designed to keep the cancer at bay. Bevacizumab is a common maintenance drug. Other times, doctors might just keep a close eye on the cancer with regular check-ups. This study is trying to understand if a new medicine, called sacituzumab tirumotecan (sac-TMT), can be a better maintenance treatment.

Sac-TMT is a type of targeted therapy, which means it's designed to specifically attack cancer cells while trying to leave healthy cells alone. The main goal of this research is to see if giving sac-TMT, either by itself or along with bevacizumab, helps women with ovarian cancer live longer without their cancer getting worse, compared to the usual treatments. This is especially for women whose cancer has responded well to their first set of treatments.

Pontos principais

  • This study is testing a new drug for advanced ovarian cancer after initial treatment.
  • It aims to see if sac-TMT (a targeted therapy) can keep cancer from worsening longer.
  • Participation involves receiving either the new drug or standard care, assigned by chance.
  • This is a Phase 3 trial, meaning it's a large study comparing the new treatment to existing ones.
  • It's for women whose cancer responded well to their first round of chemotherapy.
  • You have the right to leave the study at any time.

Quem pode ser elegível?

This study is looking for women who have advanced ovarian cancer, or similar cancers of the fallopian tube or peritoneum, that has been confirmed by a doctor. You would need to have already had surgery and completed your first course of chemotherapy, and your cancer should have responded well to that treatment – meaning it’s stable, partly gone, completely gone, or not detectable.

There are also some important health checks. For example, if you have HIV, it needs to be well-controlled. Similar rules apply if you have hepatitis B or C – these conditions need to be managed and not active. You would also need to provide a sample of your tumor tissue that hasn't been treated with radiation before.

However, there are reasons why you might not be able to join. For instance, if your cancer is a very specific type (like certain low-grade or borderline tumors), or if you have cancer that has spread to your brain or spinal cord. Other health conditions like severe eye disease, active inflammatory bowel disease needing strong medication, or serious, uncontrolled heart or blood vessel problems would also prevent you from taking part. You also can’t have had systemic cancer treatment (other than your initial chemotherapy) or certain vaccinations recently, or another type of active cancer or serious infection.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Have I been diagnosed with advanced ovarian, fallopian tube, or peritoneal cancer?
  2. Have I completed surgery and my first course of platinum-based chemotherapy?
  3. Has my cancer responded well to my first chemotherapy (stable, getting better, or undetectable)?
  4. Do I have any other serious uncontrolled health conditions like heart problems or active inflammatory bowel disease?
  5. Do I have any cancer spread to my brain or spinal cord?
  6. Am I over 18 years old and female?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you decide to take part in this study, you would first go through a screening process to make sure the study is right for you. This might involve additional hospital visits, more tests, and discussions with the study team. Once enrolled, you would receive either the study medicine (sac-TMT, with or without bevacizumab) or standard care, which could be bevacizumab or observation, depending on which group you are assigned to. This is done by chance, like flipping a coin. You'll need regular appointments, usually at the clinic, for check-ups, blood tests, and to receive your treatment. Doctors will closely monitor your health and how your cancer is responding. The duration of your participation will vary depending on your treatment plan and how your body responds. The study team will explain the full schedule of visits and assessments to you in detail.

Riscos e benefícios potenciais

Participating in research studies like this means we are hoping to find better ways to treat ovarian cancer. A potential benefit of joining could be receiving a new treatment, sac-TMT, which might keep your cancer from getting worse for longer than current treatments. However, like all medicines, sac-TMT can have side effects, which the study team will discuss with you. There’s also no guarantee that the new treatment will be better or even as good as the standard options. You could also be assigned to the standard care group. It's very important to remember that participating in any clinical trial is entirely voluntary, and you are free to withdraw at any time for any reason without it affecting your usual medical care.

Locations (177)

  • University of Alabama - Birmingham ( Site 0058)
    Código postal verificado
    Birmingham, Estados Unidos· Recrutamento
  • UCSD Moores Cancer Center ( Site 0038)
    Código postal verificado
    La Jolla, Estados Unidos· Recrutamento
  • John Muir Health Cancer Center ( Site 0069)
    Código postal verificado
    Walnut Creek, Estados Unidos· Recrutamento
  • Anschutz Cancer Pavilion ( Site 0049)
    Código postal verificado
    Aurora, Estados Unidos· Recrutamento
  • University of Colorado Health - Highlands Ranch Hospital ( Site 0094)
    Código postal verificado
    Highlands Ranch, United States· Recrutamento
  • Mount Sinai Cancer Center ( Site 0029)
    Código postal verificado
    Miami Beach, Estados Unidos· Recrutamento
  • Orlando Health Winnie Palmer Hospital for Women and Babies ( Site 0085)
    Código postal verificado
    Orlando, Estados Unidos· Recrutamento
  • Winship Cancer Institute of Emory University ( Site 0037)
    Código postal verificado
    Atlanta, Estados Unidos· Recrutamento
  • Illinois Cancer Specialists (ICS) ( Site 8009)
    Código postal verificado
    Arlington Heights, United States· Recrutamento
  • Parkview Research Center at Parkview Regional Medical Center ( Site 0055)
    Código postal verificado
    Fort Wayne, United States· Recrutamento
  • Franciscan Health Indianapolis ( Site 0081)
    Código postal verificado
    Indianápolis, Estados Unidos· Recrutamento
  • Women's Cancer Care ( Site 0018)
    Código postal verificado
    Covington, United States· Recrutamento

Perguntas frequentes

What is 'advanced ovarian cancer'?

Advanced ovarian cancer means the cancer has spread beyond the ovaries and may have reached other parts of the body.

What is a 'targeted therapy'?

A targeted therapy is a type of medicine that specifically attacks certain parts of cancer cells, aiming to cause less harm to healthy cells.

What is 'maintenance treatment'?

After initial treatment like surgery and chemotherapy, maintenance treatment is given to help keep the cancer from growing, spreading, or coming back.

Will I definitely receive the new medicine?

No, participants are randomly assigned to either receive the new study medicine (with or without bevacizumab) or standard care, such as bevacizumab or observation.

How long would I be in the study?

The length of time you'd be involved in the study can vary depending on your treatment plan and how your cancer responds. The doctors will explain this to you.

Como saber mais

Número Gratuito

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "A Clinical Trial of Sac-TMT in People With Non-HRD Positive …" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.